Sumanta Kumar Pal, MD, FASCO - Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?

Go online to PeerView.com/XZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent validation of novel multitargeted TKIs and immune checkpoint inhibitor therapies in metastatic disease, the treatment horizon of renal cell carcinoma (RCC) has vastly expanded and has continued to broaden with the emergence of long-term data supporting the efficacy of dual checkpoint blockade and combination therapies involving immunotherapy/TKI partners. Despite recent regulatory approvals, guideline updates, and abundant evidence, many medical and urologic oncologists find it challenging to bring these novel immune and targeted strategies into clinical practice. Designed to bridge the gap between theory and practice, this educational activity features expert guidance on how oncologists and urologists can integrate novel therapeutics, including immunotherapy, targeted therapy, and promising combination strategies, into the care of patients with RCC in a variety of settings. Featuring cases drawn from practice, participants will hear how peers resolve clinical issues as the faculty present best practices for individualized RCC treatment. Upon completion of this CE activity, participants will be able to: Choose appropriate, personalized treatment regimens that make use of recent clinical research findings on validated immune and targeted therapies for patients across the disease spectrum, including resectable disease, newly diagnosed metastatic, or previously treated advanced RCC, Recommend ongoing clinical trials assessing novel therapies and/or combination approaches for patients with RCC in different disease and treatment settings, Incorporate practical strategies to mitigate and manage AEs related to targeted and immune-based therapies for patients with RCC.